Does Increased Rate of Limb-sparing Surgery Affect Survival in Osteosarcoma?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The emergence of limb salvage surgery as an option for patients with osteosarcoma is attributable to preoperative chemotherapy and advancements in musculoskeletal imaging and surgical technique. While the indications for limb salvage have greatly expanded it is unclear whether limb salvage affects overall survival.
We asked whether over the past three decades limb-sparing procedures in high-grade osteosarcoma had increased, and whether this affected survival and ultimate amputation.
We retrospectively reviewed 251 patients with high-grade osteosarcoma treated from 1980 to 2004 with a multidisciplinary approach, including neoadjuvant chemotherapy. We compared survival rates, limb-salvage treatment, and amputation after limb-sparing procedure during three different periods of time. Fifty-three patients were treated from 1980 to 1989, 97 from 1990 to 1999, and 101 from 2000 to 2004. Thirty-seven patients were treated with primary amputations and 214 with primary limb salvage.
The 5-year survival rate in the first period was 36%, whereas in the 1990s, it was 60% and 67% from 2000–2004. Limb salvage surgery rate in the 1980s was 53% (28 of 53), whereas in the 1990s, it was 91% (88 of 97) and 97% from 2000–2004 (98 of 101). In the limb salvage group, 22 of the 214 patients (10%) required secondary amputation; the final limb salvage rate in the first period was 36% (19 of 53), whereas in the 1990s, it was 81% (79 of 97) and 93% from 2000–2004 (94 of 101).
Patients with osteosarcoma treated in the last two periods had higher rates of limb salvage treatment and survival, with lower secondary amputation.
Level of Evidence
Level III, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
- Aksnes LH, Bauer HC, Jebsen NL, Follerås G, Allert C, Haugen GS, Hall KS. Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 2008;90:786–794. CrossRef
- Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, Forni C, Bertoni F, Versari M, Pignotti E. Osteosarcoma of the limb. J Bone Joint Surg Br. 2002;84:88–92. CrossRef
- Bacci G, Ferrari S, Longhi A, Forni C, Bertoni F, Fabbri N, Zavatta M, Versari M. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother. 2001;13:93–99.
- Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities. A 27-year experience in a single institution. J Surg Oncol. 2007;96:118–123. CrossRef
- Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Fifteen year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–1161. CrossRef
- Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11:4666–4673. CrossRef
- Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49:101–110.
- Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21–26.
- Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.
- Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity. An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145–1150. CrossRef
- Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity. A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–8852. CrossRef
- Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP; Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580. CrossRef
- Hawkins D, Arndt C. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98:2447–2456. CrossRef
- Honegger HP, Cserhati MD, Exner GU, von Hochstetter A, Groscurth P. Zürich experience with preoperative, high dose methotrexate-containing chemotherapy in patients with extremity osteosarcomas (OSA). Ann Oncol. 1991;2:489–494.
- Huvos AG. Osteogenic Sarcoma. Bone Tumors. Diagnosis, Treatment and Prognosis. 2nd ed. Philadelphia, PA: WB Saunders; 1991:85–276.
- Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH. MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy. A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128. CrossRef
- Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991;270:8–14.
- Mercuri M, Capanna R, Manfrini M, Bacci G, Picci P, Ruggieri P, Ferruzzi A, Ferraro A, Donati D, Biagini R, de Maio M, Cazzola A, Campanacci M. The management of malignant bone tumors in children and adolescents. Clin Orthop Relat Res. 1991;264:156–168.
- Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma—the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163–2192. CrossRef
- Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am. 1986;68:1331–1337.
- Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res. 1999;358:120–127. CrossRef
- Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2124–2135. CrossRef
- Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997;79:411–415. CrossRef
- Does Increased Rate of Limb-sparing Surgery Affect Survival in Osteosarcoma?
Clinical Orthopaedics and Related Research®
Volume 468, Issue 11 , pp 2854-2859
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors